Researchers found that most patients with and without diabetes achieved less than 70 mg/dL of low-density lipoprotein cholesterol after 24 weeks of being treated with alirocumab. The findings in Diabetes Therapy, based on an analysis of five placebo-controlled phase 3 studies involving 3,459 patients with and without diabetes, revealed that 68.3% of patients with diabetes reached less than 70 mg/dL of cholesterol after receiving 75 mg of alirocumab every 2 weeks, compared with 65.8% of those without diabetes, and 78% achieved that level after receiving 150 mg, compared with 77% of those without diabetes.
Study examines safety, efficacy of alirocumab in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.